Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Sep 7 2022

Full Issue

In Unusual Move, EU Blocks $7B Merger Of 2 American Biotech Firms

A U.S. judge had already approved the merger of Illumina, headquartered in San Diego, and Grail, which is based in Menlo Park, California. The European Union says the deal would stifle innovation in an emerging market for early cancer-detection blood tests, The Wall Street Journal reported.

The Wall Street Journal: Illumina’s Deal To Buy Cancer-Test Developer Is Blocked By The EU 

The European Union blocked Illumina Inc.’s acquisition of cancer-test developer Grail Inc., putting a $7.1 billion merger into jeopardy just days after a U.S. administrative law judge allowed it to go forward. The fate of the acquisition has emerged as an early test case for regulators in the U.S. and EU who have vowed to scrutinize mergers more closely after years allowing many corporate combinations. (Mackrael and Loftus, 9/6)

In other technology news —

Reuters: Philips Recalls Some Masks Used With Respiratory Devices Over Safety Concerns 

The U.S. Food and Drug Administration said on Tuesday that medical device maker Philips has recalled certain masks used with some of its respiratory machines due to potential risk of serious injury. The masks have magnetic headgear clips or straps which can interfere with certain implanted metallic medical devices and metallic objects in the body causing potential injuries or death, the company said. (9/6)

Stat: Google Debuts A New AI Tool In The Global Fight Against Tuberculosis

Tuberculosis kills 1.4 million people every year, primarily in places where poverty and deprivation conspire to make people uniquely vulnerable, and unable to get lifesaving care in time. (Ross, 9/6)

Stat: Philip Morris Is Investing Billions In Health Care. Critics Aren't Swayed

Anew health care company was quietly incorporated last month, with plans to leverage cutting-edge inhalation technology and oral delivery expertise to treat everything from neurology to cardiovascular emergencies. (Goldhill, 9/7)

And Elizabeth Holmes wants a new trial —

The Wall Street Journal: Theranos Founder Elizabeth Holmes Seeks New Trial, Citing Fresh Evidence

Elizabeth Holmes, founder of defunct blood-testing startup Theranos Inc. who was convicted of fraud, has asked a federal judge for a new trial after she said one of the prosecution’s star witnesses visited her house to express regret for his role in her trial, according to a new court filing. Ms. Holmes said in a filing Tuesday that Adam Rosendorff, a former Theranos lab director who testified for five days in her criminal-fraud trial, showed up unannounced at her home Aug. 8. During his visit, Dr. Rosendorff spoke to Ms. Holmes’s partner and said that the government had twisted his testimony that Theranos was “working so hard to do something good and meaningful,” and that he felt guilty “to the point where he had difficulty sleeping,” according to the court filing. (Somerville, 9/6)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF